Literature DB >> 19968700

Evolution of striatal degeneration in McLeod syndrome.

P O Valko1, J Hänggi, M Meyer, H H Jung.   

Abstract

BACKGROUND AND
PURPOSE: McLeod neuroacanthocytosis syndrome (MLS) is an X-linked multisystem disorder with CNS manifestations resembling Huntington disease. Neuroimaging studies revealed striatal atrophy with predominance of the caudate nucleus. Our previous cross-sectional MRI study showed an association of volume loss in the caudate nucleus and putamen with the disease duration.
METHODS: In the present study, we examined three brothers with genetically confirmed diagnosis of MLS using an observer-independent and fully automated subcortical segmentation procedure to measure striatal volumes.
RESULTS: In a cross-sectional comparison with 20 healthy age-matched control men, the volumes of the caudate nucleus of the three patients were significantly smaller as confirmed by z-score transformations. On an individual basis, volumes in the two more severely affected and older patients were smaller than in the less affected younger brother. Longitudinal MRI-based measurements over 7 years demonstrated a statistical trend towards significant decreased caudate volumes in McLeod patients.
CONCLUSIONS: Our findings indicate that structural MRI combined with fully automated computational morphometric analyses represents an objective and observer-independent imaging tool for the representation of progressive striatal degeneration in MLS and might be a valuable methodology for cross-sectional as well as longitudinally volumetric studies in other rare neurodegenerative diseases, even on individual patients.

Entities:  

Mesh:

Year:  2009        PMID: 19968700     DOI: 10.1111/j.1468-1331.2009.02872.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

1.  Shape alterations in the striatum in chorea-acanthocytosis.

Authors:  Mark Walterfang; Jeffrey Chee Leong Looi; Martin Styner; Ruth H Walker; Adrian Danek; Marc Niethammer; Andrew Evans; Katya Kotschet; Guilherme R Rodrigues; Andrew Hughes; Dennis Velakoulis
Journal:  Psychiatry Res       Date:  2011-03-05       Impact factor: 3.222

2.  Two McLeod patients with novel mutations in XK.

Authors:  Patrycja M Dubielecka; Nelson Hwynn; Cenk Sengun; Soohee Lee; Christine Lomas-Francis; Carlos Singer; Hubert H Fernandez; Ruth H Walker
Journal:  J Neurol Sci       Date:  2011-04-03       Impact factor: 3.181

Review 3.  XK-Associated McLeod Syndrome: Nonhematological Manifestations and Relation to VPS13A Disease.

Authors:  Kevin Peikert; Andreas Hermann; Adrian Danek
Journal:  Transfus Med Hemother       Date:  2022-01-25       Impact factor: 3.747

4.  Update on the Non-Huntington's Disease Choreas with Comments on the Current Nomenclature.

Authors:  Ruth H Walker
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-01-30

Review 5.  Untangling the Thorns: Advances in the Neuroacanthocytosis Syndromes.

Authors:  Ruth H Walker
Journal:  J Mov Disord       Date:  2015-05-31

6.  Phenotypic variability in chorea-acanthocytosis associated with novel VPS13A mutations.

Authors:  Valter Niemelä; Ammar Salih; Daniela Solea; Björn Lindvall; Jan Weinberg; Gabriel Miltenberger; Tobias Granberg; Aikaterini Tzovla; Love Nordin; Torsten Danfors; Irina Savitcheva; Niklas Dahl; Martin Paucar
Journal:  Neurol Genet       Date:  2020-04-27

7.  Structural brain correlates associated with professional handball playing.

Authors:  Jürgen Hänggi; Nicolas Langer; Kai Lutz; Karin Birrer; Susan Mérillat; Lutz Jäncke
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

8.  Clinical and molecular research of neuroacanthocytosis.

Authors:  Lihong Zhang; Suping Wang; Jianwen Lin
Journal:  Neural Regen Res       Date:  2013-03-25       Impact factor: 5.135

Review 9.  Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Authors:  Patrik Fazio; Martin Paucar; Per Svenningsson; Andrea Varrone
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-05       Impact factor: 5.081

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.